Drug safety: The roles of big data and clinical experience
Abstract
Following the pharmacovigilance crises of 2004 involving the use of Vioxx and antidepressants in minors, medicine regulators turned to big data, also called real-world evidence, to support their efforts to establish the safety of treatment protocols. In many areas of drug development, big data can clearly play a part; but to date, it has not helped resolve safety issues. Developments in artificial intelligence may help clarify the respective roles of big data and clinical expertise in pharmacovigilance in surprising ways.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.